Alkermes plc. Files 8-K Report
Ticker: ALKS · Form: 8-K · Filed: 2024-04-09T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: ALKS
TL;DR
Alkermes filed an 8-K, mostly standard disclosures and exhibits.
AI Summary
On April 9, 2024, Alkermes plc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Alkermes is providing updated financial information and disclosures to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material adverse events or significant financial changes.
Key Players & Entities
- Alkermes plc. (company) — Registrant
- 0000950170-24-042791 (filing_id) — Accession Number
- April 9, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Alkermes Public Limited Company.
In which jurisdiction was Alkermes plc. incorporated?
Alkermes plc. was incorporated in Ireland.
What is the Commission File Number for Alkermes plc.?
The Commission File Number for Alkermes plc. is 001-35299.
What is the address of Alkermes plc.'s principal executive offices?
The address of Alkermes plc.'s principal executive offices is Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-04-09 07:09:35
Key Financial Figures
- $0.01 — on which registered Ordinary shares, $0.01 par value ALKS Nasdaq Global Select
Filing Documents
- alks-20240409.htm (8-K) — 49KB
- alks-ex99_1.htm (EX-99.1) — 36KB
- 0000950170-24-042791.txt ( ) — 211KB
- alks-20240409.xsd (EX-101.SCH) — 30KB
- alks-20240409_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 9, 2024, Alkermes plc (the "Company") announced positive topline results from the narcolepsy type 2 and idiopathic hypersomnia cohorts of its phase 1b study in which it evaluated ALKS 2680, the Company's novel, investigational, oral orexin 2 receptor agonist. A copy of the related press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Sta tements and Exhibits
Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release issued by Alkermes plc dated April 9, 2024. 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: April 9, 2024 By: /s/ David J. Gaffin David J. Gaffin Secretary 3